Viatris Inc
A global healthcare company that makes and sells generic medicines, complex drugs, and iconic brand-name products like Lipitor® and Lyrica®, reaching hundreds of millions of patients across more than a hundred countries. Viatris was created in 2020 when the drugmaker Mylan merged with Upjohn, the off-patent medicines arm of Pfizer, uniting two long pharmaceutical histories. It has since streamlined by selling off its women's health, over-the-counter, and active-ingredient businesses.
Granted 1.67M
Granted 237.7K · Sold 71.4K
Granted 110.6K
Granted 24.8K
Granted 24.8K
Granted 24.8K
Granted 24.8K
Granted 24.8K
Granted 129.1K · Sold 7.0K
Granted 24.8K
Granted 103.1K
Granted 24.8K
Granted 24.8K
Granted 24.8K
Granted 26.0K
Granted 26.0K
Granted 23.3K · Bought 213
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Smith Scott AndrewChief Executive Officer, Director · 14 transactions | +336.6% | 1.37M | 1.67M | — | — |
| Campbell PaulSee Remarks · 16 transactions | +24.4% | 316.5K | 237.7K | — | 71.4K |
| Enrietti AndrewSee Remarks · 14 transactions | +75% | 227.5K | 110.6K | — | — |
| Higgins Melina EDirector · 2 transactions | +13.2% | 220.0K | 24.8K | — | — |
| Parrish Mark WDirector · 2 transactions | +18.3% | 165.2K | 24.8K | — | — |
| Kilts James MDirector · 2 transactions | +18.9% | 161.3K | 24.8K | — | — |
| Mark Richard ADirector · 2 transactions | +27% | 115.0K | 24.8K | — | — |
| Cornwell W DonDirector · 2 transactions | +39.5% | 112.0K | 24.8K | — | — |
| Le Goff CorinneChief Commercial Officer · 13 transactions | +79.9% | 108.8K | 129.1K | — | 7.0K |
| Lyons Dillon JoEllenDirector · 2 transactions | +32% | 102.5K | 24.8K | — | — |
| Mistras TheodoraChief Financial Officer · 12 transactions | +277.4% | 92.8K | 103.1K | — | — |
| Groothuis Leo FransDirector · 4 transactions | +57.2% | 63.4K | 24.8K | — | — |
| Finney Elisha WDirector · 2 transactions | +65.9% | 61.5K | 24.8K | — | — |
| Vivaldi Coelho RogerioDirector · 2 transactions | +113.2% | 45.4K | 24.8K | — | — |
| Damelio Frank ADirector · 2 transactions | — | 26.0K | 26.0K | — | — |
| Severino MichaelDirector · 2 transactions | — | 26.0K | 26.0K | — | — |
| Simmons David SDirector · 3 transactions | — | 23.5K | 23.3K | 213 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -78.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.